ClinicaliQ Trial Snapshot
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations — Recruiting • Phase I • Oncology • NCT06892522.
- What is being tested: The safety and efficacy of T cell engaging bi/tri-specific antibodies administered intravenously or subcutaneously, either as monotherapy or in combination regimens, to assess disease activity changes and adverse events in adult multiple myeloma patients.
- Patient eligibility overview: Adult participants with multiple myeloma who meet specific disease activity and performance criteria; exact inclusion/exclusion parameters would be detailed in the full protocol but typically encompass newly diagnosed, relapsed, or relapsed-refractory disease populations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of…
Eligibility Snapshot
- : * Eastern cooperative oncology group (ECOG) performance of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.